outcomes of allohsct in tp53-mutated aml and mds
Published 2 years ago • 636 plays • Length 1:40Download video MP4
Download video MP3
Similar videos
-
2:24
the challenges of treating tp53-mutated aml and mds
-
2:26
impact of allelic state on os in tp53-mutant aml and hr-mds
-
2:36
outcomes of tp53-mutant aml with venetoclax and decitabine
-
5:16
an analysis of tp53 mutation in aml and hr-mds
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
3:22
is tp53-mutated high-risk mds the same disease as tp53-mutated aml?
-
0:33
unmet needs in mds: treating relapse after allohsct & tp53-mutated disease
-
1:57
the benefit of allogeneic transplantation in patients with tp53-mutated aml
-
25:01
3mensio ct pre-case planning: redo-tavr with prior sapien 3 (1 of 2)
-
6:55
dmf section 3.2.s.7 - stability
-
3:56
treatment approaches for patients with tp53-mutated mcl
-
8:14
progress in the treatment of tp53 mutated aml
-
1:57
tolerability and efficacy of magrolimab plus azacitidine in tp53-mutated aml patients
-
1:59
depth of molecular response in patients with tp53m mds & aml treated with magrolimab and azacitidine
-
1:20
impact of tp53 mutations on outcomes in myelofibrosis
-
3:00
apr-246 in tp53 mutated mds and aml
-
2:23
improving treatment for patients with tp53-mutated myeloid malignancies
-
1:25
should patients with tp53-mutated mds receive stem cell transplant?
-
1:13
targeting p53 in mds
-
0:58
options available to patients with tp53-mutated mds beyond stem cell transplantation
-
1:23
immunological impact of tp53 in mds
-
2:58
long-term follow-up: phase ii study of apr-246 aza in tp53-mutated mds & aml